Tainan, Taiwan – Each year, about 528,000 new cases of cervical cancer are reported worldwide. In Taiwan, a screening program exists for early detection, which can save life-years for those individuals who are affected, but the effect on quality of life still remains to be quantified.
In the article, “Estimation of Potential Gain in Quality of Life from Early Detection of Cervical Cancer,” published in Value in Health, investigators abstracted data of 22,543 new cases of invasive cervical cancer (ICC) from the Taiwan National Cancer Registry to estimate the lifetime survival function, as well as a consecutive, cross-sectional sample of 421 patients with ICC or carcinoma in situ (CIS) to measure the QOL. The ratio of QOL score functions for ICC and CIS patients were summed up over lifetime to obtain the duration of suffering from unsatisfactory HRQL.
Jung-Der Wang MD, ScD, from the National Cheng Kung University Medical College and Hospital, lead author of the study, states, “In comparison with invasive cervical cancer, early detection of cervical neoplasm at the pre-cancer (carcinoma in situ, CIS) stage not only avoids 6.48 years of life loss, but also prevents reduction in HRQL in the long-run, leading to HRQL gains in the physical (1.71 years) and psychological (0.25 years) domains, as well as sexual life (1.47 years).”
Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.
Follow Value in Health on Twitter: @ISPORJournals
For more information: www.ispor.org